JP2006527193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527193A5 JP2006527193A5 JP2006515022A JP2006515022A JP2006527193A5 JP 2006527193 A5 JP2006527193 A5 JP 2006527193A5 JP 2006515022 A JP2006515022 A JP 2006515022A JP 2006515022 A JP2006515022 A JP 2006515022A JP 2006527193 A5 JP2006527193 A5 JP 2006527193A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf
- composition
- corticosteroid
- inhibitor
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056852 Myostatin Proteins 0.000 claims 49
- 102000004472 Myostatin Human genes 0.000 claims 49
- 239000003112 inhibitor Substances 0.000 claims 33
- 239000003246 corticosteroid Substances 0.000 claims 29
- 241000124008 Mammalia Species 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 210000003205 muscle Anatomy 0.000 claims 9
- 102000016970 Follistatin Human genes 0.000 claims 7
- 108010014612 Follistatin Proteins 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 201000006938 muscular dystrophy Diseases 0.000 claims 6
- 230000005996 muscular dysfunction Effects 0.000 claims 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 229960004618 prednisone Drugs 0.000 claims 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 150000003384 small molecules Chemical class 0.000 claims 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims 3
- 208000010428 Muscle Weakness Diseases 0.000 claims 3
- 206010028372 Muscular weakness Diseases 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 230000004220 muscle function Effects 0.000 claims 3
- 208000018360 neuromuscular disease Diseases 0.000 claims 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 102100036001 G-protein coupled receptor-associated sorting protein 1 Human genes 0.000 claims 2
- 101710142641 G-protein coupled receptor-associated sorting protein 1 Proteins 0.000 claims 2
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 2
- 101710160038 WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 Proteins 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 210000004165 myocardium Anatomy 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47460303P | 2003-06-02 | 2003-06-02 | |
| US60/474,603 | 2003-06-02 | ||
| PCT/US2004/017049 WO2004108157A2 (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007160708A Division JP2007238631A (ja) | 2003-06-02 | 2007-06-18 | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006527193A JP2006527193A (ja) | 2006-11-30 |
| JP2006527193A5 true JP2006527193A5 (enExample) | 2007-04-19 |
| JP5110877B2 JP5110877B2 (ja) | 2012-12-26 |
Family
ID=33511616
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515022A Expired - Fee Related JP5110877B2 (ja) | 2003-06-02 | 2004-06-01 | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| JP2007160708A Pending JP2007238631A (ja) | 2003-06-02 | 2007-06-18 | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007160708A Pending JP2007238631A (ja) | 2003-06-02 | 2007-06-18 | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7785587B2 (enExample) |
| EP (1) | EP1635870A2 (enExample) |
| JP (2) | JP5110877B2 (enExample) |
| KR (1) | KR20060026860A (enExample) |
| CN (1) | CN1829532A (enExample) |
| AU (1) | AU2004245025A1 (enExample) |
| BR (1) | BRPI0410927A (enExample) |
| CA (1) | CA2526669A1 (enExample) |
| CO (1) | CO5660274A2 (enExample) |
| EC (1) | ECSP066268A (enExample) |
| MX (1) | MXPA05012965A (enExample) |
| NO (1) | NO20056252L (enExample) |
| RU (1) | RU2322261C2 (enExample) |
| UA (1) | UA85055C2 (enExample) |
| WO (1) | WO2004108157A2 (enExample) |
| ZA (1) | ZA200510456B (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| US7785587B2 (en) * | 2003-06-02 | 2010-08-31 | Wyeth | Therapeutic methods for muscular or neuromuscular disorders |
| EP1729793B1 (en) * | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| EA201100642A1 (ru) | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| PT2407486T (pt) | 2005-08-19 | 2018-02-21 | Univ Pennsylvania | Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8 |
| CN101277976B (zh) * | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| WO2008018795A1 (en) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| UA98308C2 (en) * | 2006-09-05 | 2012-05-10 | Эли Лилли Энд Компани | Anti-myostatin antibody |
| EP2468291B1 (en) | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| AU2008273096B2 (en) | 2007-07-12 | 2013-05-02 | Academisch Ziekenhuis Leiden | Molecules for targeting compounds to various selected organs or tissues |
| CN101790385A (zh) | 2007-07-12 | 2010-07-28 | 普罗森那技术公司 | 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子 |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| PT2203173E (pt) | 2007-10-26 | 2016-03-15 | Academisch Ziekenhuis Leiden | Resumo |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| EP2249874A1 (en) | 2008-02-08 | 2010-11-17 | ProSensa Holding BV | Methods and means for treating dna repeat instability associated genetic disorders |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US20100008918A1 (en) | 2008-06-26 | 2010-01-14 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| ME02652B (me) | 2008-11-26 | 2017-06-20 | Amgen Inc | Stabilizovana varijanta aktivin iib receptora |
| EP2387412A4 (en) * | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| NZ595955A (en) | 2009-04-24 | 2012-10-26 | Prosensa Technologies Bv | Oligonucleotide comprising an inosine for treating dmd |
| NO2424895T3 (enExample) * | 2009-04-27 | 2018-02-03 | ||
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| US8945511B2 (en) * | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| CA2773494A1 (en) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| US9845512B2 (en) * | 2010-01-15 | 2017-12-19 | Rigel Pharmaceuticals, Inc. | Screening assay employing Dex and GDF8 |
| US20110268736A1 (en) * | 2010-04-30 | 2011-11-03 | Children's Medical Center Corporation | Method for treating congenital myopathy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| NZ627896A (en) | 2012-01-27 | 2016-11-25 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| US9506033B2 (en) | 2012-05-22 | 2016-11-29 | University Of Massachusetts | Compositions and methods for inducing myoblast differentiation and myotube formation |
| WO2013186719A1 (en) | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| CA2899889A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
| NZ732507A (en) * | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US9862752B2 (en) * | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| WO2015187977A1 (en) | 2014-06-04 | 2015-12-10 | Acceleron Pharma, Inc. | Methods and compositions for treatment of disorders with follistatin polypeptides |
| AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| SMT202300166T1 (it) | 2014-12-03 | 2023-07-20 | Celgene Corp | Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| WO2016154601A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| KR20170074604A (ko) | 2015-12-22 | 2017-06-30 | 삼성전자주식회사 | 근육 소모 관련 질환을 예방 또는 치료하기 위한 조성물 및 그의 용도 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| KR102457751B1 (ko) | 2016-03-10 | 2022-10-21 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| US11248044B2 (en) | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US150577A (en) * | 1874-05-05 | Improvement in grain-separators | ||
| US4370976A (en) * | 1980-06-03 | 1983-02-01 | Contour Fabricators, Inc. | Dynamic foam orthosis |
| US5130141A (en) * | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| GB9211085D0 (en) * | 1992-05-23 | 1992-07-08 | Tippey Keith E | Electrical stimulation |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US6673534B1 (en) | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US20030074680A1 (en) | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| PT698094E (pt) | 1993-05-12 | 2004-05-31 | Inst Genetics Llc | Composicoes de bmp-11 |
| US5731415A (en) * | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
| DK0716610T3 (da) | 1993-08-26 | 2006-09-04 | Genetics Inst Llc | Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering |
| US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US7332575B2 (en) | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| CA2194660C (en) * | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| DE69841139D1 (de) | 1997-07-14 | 2009-10-22 | Univ Liege | Mutationen im myostatingen steigern muskelmasse in säugetieren |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| EP1015468A4 (en) | 1997-08-29 | 2000-09-06 | Human Genome Sciences Inc | FOLLISTATINE-3 |
| AU1276399A (en) | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
| WO1999024618A1 (en) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| WO2000011163A1 (en) | 1998-08-20 | 2000-03-02 | Regeneron Pharmaceuticals, Inc. | Dcr5, a bmp-binding protein, and applications thereof |
| BR0008188A (pt) | 1999-01-21 | 2002-02-13 | Metamorphix Inc | Inibidores de fator de diferenciação de crescimento e usos para os mesmos |
| EE200200025A (et) | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
| WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
| US6649588B1 (en) * | 2000-10-05 | 2003-11-18 | North Shore - Long Island Jewish Research Institute | Inhibition of TGF-β and uses thereof |
| US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US6552172B2 (en) | 2001-08-30 | 2003-04-22 | Habto Biotech, Inc. | Fibrin nanoparticles and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| MXPA04008149A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Proteinas que contienen dominios de folistatina. |
| MXPA04008150A (es) | 2002-02-21 | 2005-06-17 | Wyeth Corp | Gasp1: una proteina que contiene dominio de folistatina. |
| BR0314270A (pt) | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| US7785587B2 (en) * | 2003-06-02 | 2010-08-31 | Wyeth | Therapeutic methods for muscular or neuromuscular disorders |
| US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| BRPI0609449A2 (pt) | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de agentes de modulação de gdf-8 |
| JP2008537777A (ja) | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
-
2004
- 2004-06-01 US US10/858,353 patent/US7785587B2/en not_active Expired - Fee Related
- 2004-06-01 UA UAA200512673A patent/UA85055C2/ru unknown
- 2004-06-01 EP EP04753802A patent/EP1635870A2/en not_active Withdrawn
- 2004-06-01 CN CNA2004800221348A patent/CN1829532A/zh active Pending
- 2004-06-01 KR KR1020057023105A patent/KR20060026860A/ko not_active Withdrawn
- 2004-06-01 WO PCT/US2004/017049 patent/WO2004108157A2/en not_active Ceased
- 2004-06-01 JP JP2006515022A patent/JP5110877B2/ja not_active Expired - Fee Related
- 2004-06-01 AU AU2004245025A patent/AU2004245025A1/en not_active Withdrawn
- 2004-06-01 MX MXPA05012965A patent/MXPA05012965A/es active IP Right Grant
- 2004-06-01 RU RU2005141434/14A patent/RU2322261C2/ru not_active IP Right Cessation
- 2004-06-01 CA CA002526669A patent/CA2526669A1/en not_active Abandoned
- 2004-06-01 BR BRPI0410927-9A patent/BRPI0410927A/pt not_active IP Right Cessation
-
2005
- 2005-12-22 ZA ZA200510456A patent/ZA200510456B/xx unknown
- 2005-12-30 NO NO20056252A patent/NO20056252L/no not_active Application Discontinuation
- 2005-12-30 CO CO05131698A patent/CO5660274A2/es not_active Application Discontinuation
-
2006
- 2006-01-02 EC EC2006006268A patent/ECSP066268A/es unknown
-
2007
- 2007-06-18 JP JP2007160708A patent/JP2007238631A/ja active Pending
-
2010
- 2010-08-27 US US12/869,917 patent/US20100322942A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006527193A5 (enExample) | ||
| RU2005141434A (ru) | Применение ингибиторов миостатика (gdf8) в сочетании кортикостероидами для лечения нервно-мышечных заболеваний | |
| JP6744891B2 (ja) | コルチコステロイド組成物 | |
| JP2008535841A5 (enExample) | ||
| JP2013518908A5 (enExample) | ||
| EP2379081B1 (en) | Treatment of diarrhoea | |
| JP2017511793A5 (enExample) | ||
| JP2011503075A5 (enExample) | ||
| JP2020524670A5 (enExample) | ||
| JP2020502219A5 (enExample) | ||
| US7361646B2 (en) | Methods for treating gastroesophageal reflux disease | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| US20120245552A1 (en) | Combination Therapy | |
| JP2007505829A5 (enExample) | ||
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| JP2011506607A (ja) | 免疫炎症性障害の処置のための治療法 | |
| JP2007506681A5 (enExample) | ||
| JP2014521634A (ja) | Ｔｒｐａ１アンタゴニスト及びステロイドを含む医薬組成物 | |
| AU2013338305B2 (en) | Methods and compositions for treating progesterone-dependent conditions | |
| D. Wolthers | Relevance of pharmacokinetics and bioavailability of intranasal corticosteroids in allergic rhinitis | |
| LeVee et al. | New drugs, new toxicities: side effects of new and emerging breast cancer therapies | |
| CN107007580A (zh) | 用于治疗肌肉萎缩症的化合物 | |
| JP2014528458A (ja) | 鼻炎の治療 | |
| Zöllner | Is adrenal suppression in asthmatic children reversible? A case series | |
| Gunasekera et al. | Su2089 An IgG4 Specific Food Exclusion Diet Improves Both Clinical Disease Activity and Quality of Life in Crohn's Disease; a Randomised Sham Diet Controlled Study |